Zura Bio Earnings Call Transcripts
Fiscal Year 2026
-
The company is prioritizing tibulizumab, a first-in-class bispecific antibody targeting IL-17 and BAFF, with pivotal phase II data in hidradenitis suppurativa expected in Q4 and systemic sclerosis data in the first half of 2027. Strategic focus is on robust trial design, market differentiation, and readiness for phase III advancement.
-
Leadership transition brings renewed focus on tibulizumab, a bispecific antibody targeting IL-17A and BAFF, with pivotal phase II readouts in hidradenitis suppurativa and systemic sclerosis expected in the next 12-18 months. Robust study design and pipeline expansion are prioritized.
Fiscal Year 2025
-
The conference highlighted progress on a lead bispecific antibody in Phase II trials for hidradenitis suppurativa and systemic sclerosis, with top-line data expected late next year. Financial resources are sufficient through 2027, and strategic decisions on pipeline assets and future financing hinge on upcoming trial results.
-
Two phase 2 trials for systemic sclerosis and hidradenitis suppurativa are underway, both leveraging tibulizumab's dual IL-17 and BAFF inhibition. Top-line data are expected in 2026, with a strong cash position supporting operations through 2027.
-
The company is advancing bispecific antibody programs in scleroderma and hidradenitis suppurativa, with phase II trials underway and data expected in 2026. Strong cash reserves support ongoing development, and the pipeline includes additional assets targeting IL-7, TSLP, and IL-33.
Fiscal Year 2024
-
Three key assets are advancing, with ZB-106 prioritized for SSC and HS, and major catalysts expected from Q32, Novartis BAFF, and IL-33 COPD readouts in 2025. Rigorous study design, validated targets, and a focus on bispecific antibodies position the pipeline for rapid progress.
-
The company is advancing bispecific antibody assets, with pivotal Phase II trials for SSc and HS set to begin soon and readouts expected in 2026. Strong scientific rationale supports their lead programs, and $190M in cash secures funding through 2027.
-
The company is advancing three phase II-ready assets targeting autoimmune diseases, with key studies in systemic sclerosis and hidradenitis suppurativa set to begin in late 2024 and early 2025. Differentiation is based on multifunctional antibodies and superior Fc function, with strategic partnering decisions tied to upcoming competitor data.
-
Three in-licensed assets target autoimmune and inflammatory diseases with novel mechanisms, including dual IL-17/BAFF and IL-7/TSLP antagonists. Phase II trials for systemic sclerosis and hidradenitis suppurativa are planned, with $188M in cash runway through 2027.
-
Significant progress has been made in advancing dual pathway biologics for autoimmune diseases, with two major clinical trials set to launch for systemic sclerosis and hidradenitis suppurativa. Strong scientific rationale, robust funding, and differentiated assets position the pipeline for potential first-in-class therapies.